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Todeﬁne themechanismsbywhichhPrP90-231inducescelldeath,weanalyzeditsinteractionwithlivingcellsandmonitoredits
intracellular fate. Treatment of SH-SY5Y cells with ﬂuorescein-5-isothiocyanate (FITC)-conjugated hPrP90-231 caused the
accumulation of cytosolic aggregates of the prion protein fragment that increased in number and size in a time-dependent
manner. The formation of large intracellular hPrP90-231 aggregates correlated with the activation of apoptosis. hPrP90-231
aggregatesoccurredwithinlysotracker-positivevesiclesandinducedtheformationofactivatedcathepsinD(CD),indicatingthat
hPrP90-231 is partitioned into the endosomal–lysosomal system structures, activating the proteolytic machinery. Remarkably,
the inhibition of CD activity signiﬁcantly reduced hPrP-90-231-dependent apoptosis. Internalized hPrP90-231 forms detergent-
insoluble and SDS-stable aggregates, displaying partial resistance to proteolysis. By confocal microscopy analysis of lucifer
yellow (LY) intracellular partition, we show that hPrP90-231 accumulation induces lysosome destabilization and loss of
lysosomal membrane impermeability. In fact, although control cells evidenced a vesicular pattern of LY ﬂuorescence (index of
healthy lysosomes), hPrP90-231-treated cells showed diffuse cytosolic ﬂuorescence, indicating LY diffusion through damaged
lysosomes. In conclusion, these data indicate that exogenously added hPrP90-231 forms intralysosomal deposits having
features of insoluble, protease-resistant aggregates and could trigger a lysosome-mediated apoptosis by inducing lysosome
membrane permeabilization, followed by the release of hydrolytic enzymes.
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Subject Category: Neuroscience
Transmissible spongiform encephalopathies (TSE) are fatal
neurodegenerative disorders characterized by spongiform
degeneration of the brain, neuronal loss, gliosis, and amyloid
deposition. According to the ‘protein only’ hypothesis, TSEs
share, as crucial pathogenic event, the posttranslational
misfolding of a membrane-anchored glycoprotein (cellular
prion protein, PrP
C) into a protease-resistant, aggregation-
prone isoform (PrP
Sc).
1 PrP
Sc is thought to be the main, if not
the sole, component of the infectious entity of TSE (the prion).
PrP
C–PrP
Sc conversion, physiologically prevented by energy
barrier, may be a spontaneous stochastic event, favored by
mutations in the PRNP gene, or acquired by infection with
exogenous PrP
Sc. PrP
Sc resistance to proteolysis determines
its deposition, as partially cleaved protein, in extracellular
space and the formation of amyloid plaques.
1 PrP
Sc deposits
are often identiﬁed in proximity of neuronal rarefaction and
gliosis, suggesting their possible involvement in inﬂammatory
and apoptotic cascades.
2 Recombinant PrP fragments
corresponding to the protease-resistant portion of PrP
Sc have
beenusedtostudyPrPpathogenicrefoldingandneurotoxicity
being characterized by a ﬂexible backbone that can undergo
conformational rearrangement resembling PrP
C–PrP
Sc
conversion.
3,4 Although a deﬁnitive agreement is still lacking,
it was demonstrated that PrP
Sc-like fragments can generate
disease after cerebral inoculation in rodents.
5,6 We generated
a recombinant protein encompassing residues 90-231 of
human PrP (hPrP90-231) that, in its native form, is a soluble
monomer, mainly structured as a-helix.
7 Controlled thermal
denaturation (1h at 531C) converts hPrP90-231 in a b-sheet-
rich conformation that renders the peptide insoluble, highly
hydrophobic, and partially resistant to proteolysis.
3,8 These
biochemical features, resembling PrP
Sc-like structure, allow
hPrP90-231 to acquire biological activities in vitro, inducing
microglial activation, astrocyte proliferation, and neuron
apoptosis,
3,9 thus, representing a valuable model to study
prion neurotoxicity and the potential development of novel
therapeutics.
10,11
To deﬁne the mechanism of hPrP90-231 effects on cell
viability, we used SH-SY5Y human neuroblastoma cells.
These cells are sensitive to PrP fragment toxicity through the
intracellular accumulation of hPrP90-231 oligomers within the
vesicular system.
3,12 The identiﬁcation of intracellular
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www.nature.com/cddishPrP90-231 deposits was a relevant starting point of this
study as intracellular accumulation of misfolded and unclea-
vable proteins represents a pathogenetic event in several
neurodegenerative disorders.
13 Misfolded PrP deposits were
described inside neuron cell bodies and in correspondence
with axons and dendrites,
14 being involved in neuronal
apoptosis by perturbing energy metabolism, protein home-
ostasis, or axonal transport. TSE-related neuronal rarefaction
occurs in brain areas characterized by lysosomal overloading
with PrP
Sc,
15,16 suggesting that released lysosome proteases
may contribute to neuronal death. Lysosome membrane
permeabilization,releasingcathepsins,elicitstheactivation of
proteins (caspases, BID, XIAPs),
17 crucial for mitochondria-
mediated apoptosis. Cathepsin release from lysosomes is
triggered by several proapoptotic stimuli, including oxidative
stress, cytotoxic drugs,
18 and also after Ab1-42 intracellular
accumulation in Alzheimer disease models.
19
To address lysosome involvement in hPrP90-231
neurotoxicity, we treated SH-SY5Y cells with a ﬂuorescein-
5-isothiocyanate (FITC)-tagged form of this peptide (hPrP90-
231-FITC) and monitored, by live cell imaging, its intracellular
accumulation. We show that hPrP90-231-FITC accumulates
in the endosomal–lysosomal system and activates cathepsin
D (CD). hPrP90-231-FITC intracellular accumulation was
correlated with the detection of apoptosis, suggesting that
lysosomal overloading is a causal event in SH-SY5Y cell
death. Indeed, pharmacological inhibition of CD reduced
hPrP90-231 apoptosis.
These data indicate that hPrP90-231 toxicity is mediated by
lysosome-dependent apoptosis stimulated by lysosome over-
loading with proteolysis-insensitive protein aggregates.
Results
PrP90-231-FITC accumulates in SH-SY5Y cytoplasm in
time-dependent manner as membrane-surrounded
aggregates. Thermally denatured b-sheet-rich hPrP90-231
oligomers induce apoptosis in SH-SY5Y cells through the
cytoplasmic accumulation of the peptide.
12,20
Here, we used a FITC-tagged hPrP90-231 to precisely
identify its subcellular localization and discriminate between
the recombinant fragment and endogenous PrP
C. Prelimina-
rily, we veriﬁed that the FITC tag did not alter the physico-
chemical and biological features of hPrP90-231, showing that
it retains partial resistance to proteinase K (PK) digestion and
conformation-dependent cytotoxicity, with efﬁcacy similar to
the untagged peptide (data not shown).
To investigate the mechanisms of hPrP90-231-FITC
activation of apoptosis, we analyzed, by confocal microscopy,
the presence of cytosolic aggregates of internalized PrP
fragment (Figure 1a). Cells treated with thermally denatured
hPrP90-231-FITC showed numerous intracytoplasmic ﬂuor-
escent spots that became large clusters, in a time-dependent
manner. FITC-conjugated a-helix-structured hPrP90-231
accumulated in SH-SY5Y cytoplasm at lower rate than
b-sheet-rich hPrP90-231-FITC, resulting in smaller aggregates
(Figure 1a). We quantiﬁed the cell number that internalized
the two hPrP90-231-FITC conformers (Figure 1b) showing
that, after 24h of treatment, the b-sheet-rich PrP fragment
was accumulated in the double of the cells that internalized
the a-helix-structured hPrP90-231.
To detect whether hPrP90-231 intracellular accumulation
was caused by entrapment within the vesicular system or by
protein aggregation into the cytosol, we incubated SH-SY5Y
cells with the lipophilic dye 1,10-dioctadecyl-3,3,30,30-tetra-
methylindocarbocyanine perchlorate (DiI) before hPrP90-
231-FITC treatment (Figure 1c). Live cell imaging showed
that hPrP90-231 binds to the cell membrane within 5min and
can be recovered, after 6h, into the cytosol as discrete
clusters colocalizing with the membrane ﬂuorescent probe
(Figure 1c). After longer treatments, large hPrP90-231-FITC
clusters, clearly surrounded by DiI ﬂuorescence, were
detected, indicating that intracellular hPrP90-231 aggregates
are caged into membrane-coated vesicles. Conversely, we
did not detect hPrP90-231 aggregates not colocalized with
DiI, signifying that hPrP90-231 does not diffuse through the
plasma membrane to aggregate into the cytosol.
SH-SY5Y overloading with hPrP90-231 correlates with
the activation of the apoptotic process. Then, we
quantiﬁed the time- and structure-dependency of hPrP90-
231-induced apoptosis, measuring by ELISA, the cytosolic
oligonucleosomes released by apoptotic endonucleases. We
show that a-helix-structured hPrP90-231 induced modest
DNA cleavage, only after 3 days of treatment. In contrast, cell
exposure to b-sheet-structured hPrP90-231 caused a
signiﬁcant accumulation of cytosolic oligonucleosomes
already after 24h, reaching its maximal effect after
3 days of treatment (about threefolds higher than controls,
Table 1).
To correlate hPrP90-231 intracellular accumulation and
activation of apoptosis, we treated SH-SY5Y cells with
hPrP90-231-FITC and assessed, in live cell imaging, the
onset of apoptosis by annexin-V binding test (Figure 2).
Control cells did not show annexin-V binding to the mem-
brane, indicating the absence of apoptotic cells within the
culture. Conversely, hPrP90-231-FITC treatment (100nM,
72h) caused a strong annexin-V staining on the plasma
membrane, indicating the activation of apoptosis in a
signiﬁcant number of cells. Annexin-V-positive cells showed
round and shrunk bodies (typical of apoptotic cells) and
evidenced high amounts of internalized hPrP90-231-FITC
(Figure 2-B, yellow arrows), whereas cells that internalized
low levels of peptide did not undergo to apoptosis (Figure 2,
white arrows). We estimated that, for each given time point,
more than 10% of treated cells were annexin-V and hPrP90-
231-FITC-positive, although the low adherence of apoptotic
cellssurelycausedunderestimation ofthe total apoptotic cells
number. Thus, hPrP90-231 induces apoptosis when a high
hPrP90-231n cell loading occurs, whereas the interaction
between hPrP90-231 and plasma membrane may not induce
per se neurotoxicity if it is not followed by internalization of the
PrP fragment.Tobetterquantifytheextent ofapoptosislinked
to hPr90-231 internalization, we measured, by ﬂow cyto-
ﬂuorimetry, the percentage of cells showing overlapping
hPrP90-231-FITC and annexin-V staining. We treated
SH-SY5Y cells with b-sheet-rich hPrP90-231-FITC (1mM,
3 days), before annexin-V staining (Figure 2, lower panels).
Only 4% of control cells were annexin-V positive (Figure 2A,
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Cell Death and Diseaselower panel, R2), indicating low amount of spontaneous
apoptosis. hPrP90-231-FITC-treated cells showed annexin-V
binding in 11.37% of cells (Figure 2B, lower panel, R3), thus
indicating a threefold increase of apoptosis compared with
controls.Importantly,almostalltreatedcellswerestainedwith
hPrP90-231-FITC (Figure 2B, lower panel, R3þR5), but only
part of them entered the apoptotic pathway in agreement with
the observation (Figure 2 upper panels) that elevated
intracellular accumulation of hPrP90-231 is required to induce
cell death.
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Figure 1 hPrP90-231 accumulates in SH-SY5Y in a structure-dependent manner. (a) Cells were plated on glass coverslips and treated for 24–72h with a– and
b–hPrP90-231-FITC (100nM). After treatments, cells were ﬁxed and immunostained for a-tubulin to evidence the cell shape. Images, representative of at least three
experiments,showthatb–hPrP90-231-FITCisinternalizedasintracellularﬂuorescentclustersthatcondensedinatime-dependentmanner.Conversely,a–hPrP90-231-FITC
treatment caused the internalization of small ﬂuorescent clusters that did not evidence a signiﬁcant condensation. (Scale bar¼10mm). (b) Structure-dependent hPrP90-231
internalization. After exposure to a–( J) and b–( K) hPrP90-231-FITC (100nM) for 6, 24, and 48h, cells containing ﬂuorescent clusters have been counted and plotted as
percentages of total cells. The percent of cells showing intracellular FITC after exposure to b–hPrP90-231-FITC is signiﬁcantly higher than that observed in cells treated with
a–hPrP90-231-FITC. Values represent the averages of three experiments conducted counting at least 500 cells/dish. *Po0.05, **Po0.01 versus a–hPrP90-231-FITC -
treated cells. (c) Live cell imaging of hPrP90-231-FITC intracellular accumulation in the presence of the membrane dye DiI. Cells were plated in glass-bottom Petri dishes,
loaded with membrane-speciﬁc ﬂuorescent dye DiI for 1h, and incubated with b–hPrP90-231-FITC (100nM). Images (representative of three experiments) show that
b–hPrP90-231-FITC binding to plasma membranes occur within few minutes. Treatment with b–hPrP90-231-FITC for 6h evidenced the presence of intracellular ﬂuorescent
clustersthat colocalizes with the membrane-speciﬁcprobe DiI, indicating that b–hPrP90-231 accumulates in membrane-coated vesicles. Treatments for 24 and 48h resulted
in the intracellular accumulation of large FITC-stained, round clusters almost completely colocalizing with DiI. (Scale bar¼10mm)
Table 1 Induction of apoptosis in SH-SY5Y cells by hPrP90-231
Days of treatment 1 2 3 4
a-hPrP90-231 102±0.3 112±0.21 133±0.2* 120±0.15*
b-hPrP90-231 127±0.19*
O 190±0.13**
OO 297±0.12**
OO 250±0.3**
OO
hPrP90-231, innativestructure(a-hPrP90-231)orinab-sheet-rich conformation (b-hPrP90-231), wasused atthe concentration of1mM.Apoptosis wasquantiﬁed by
cytosolic oligonucleosome ELISA, after 1–4 days. Data were expressed as percentage of PBS-treated controls and represents the average of three independent
experiments performed in quadruplicate *Po0.05, **Po0.01 versus cont. values.
OPo0.05,
OOPo0.01 versus samples treated with a-hPrP90-231
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Cell Death and DiseaseInternalized hPrP90-231 forms SDS-stable aggregates. We
used semi-denaturing detergent-agarose gel electrophoresis
to assess the formation of hPrP90-231 intracellular
aggregates.
20–22 SH-SY5Y cells, treated with vehicle or
hPrP90-231 (1mM) were lysed and protein electrophoresis
performed in non-denaturing conditions to preserve hPrP90-
231 intermolecular bonds and separate aggregates according
to the their dimensions (Figures 3a and b). A separate set of
samples was denatured and resolved by a standard SDS-
PAGE to identify the molecular weight of endogenous PrP
C and
internalized hPrP90-231 (Figures 3c and d). We also used two
antibodies able to discriminate hPrP90-231 from PrP
C;3 F 4
antibody recognizes both proteins, 8B4 antibody labels the ﬁrst
60–80 a.a. of PrP and does not detect hPrP90-231. In control
cells, 3F4 and 8B4 evidenced two discrete bands, likely
corresponding to endogenous PrP
C (Figures 3a and b, lanes
2). In treated cells, large hPrP90-231 aggregates were detected
as 3F4-reactive proteins of high molecular weight (Figure 3a,
lanes 3, 4), but distributed throughout the electrophoretic lanes,
indicating that internalized hPrP90-231 is recovered in
macroaggregated complexes of different size. hPrP90-231
intracellular content and electrophoretic mobility were similar
after 1 or 4 days of treatment (Figure 3a, lanes 3, 4),
demonstrating that hPrP90-231 aggregation state is not
signiﬁcantly affected by cell catabolic machinery. 8B4-
immunoreactive signal in hPrP90-231-treated cells was not
changed with respect to controls (Figure 3b, lanes 3, 4)
signifying that PrP
C does not aggregate after hPrP90-231
internalization. SDS-PAGE showed that intracellular hPrP90-
231 aggregates are composed by 16kDa monomers
(Figure 3c) and do not alter PrP
C expression (Figure 3d).
Intracellular hPrP90-231 aggregates are insoluble in
non-denaturing detergents. Solubility in non-denaturing
detergents is a commonly used parameter that discriminates
PrP
C from PrP
Sc, the latter being less soluble.
23 Structural
alterations induced by hPrP90-231 thermal denaturation
results in increased exposure of hydrophobic residues to the
solvent in cell-free experiments.
4 To obtain an index of the
hydrophobicity of hPrP90-231 intracellular aggregates, we
measured detergent solubility of internalized hPrP90-231.
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Figure2 SH-SY5YoverloadingwithhPrP90-231correlateswithapoptosisonset.Upperpanels.LivecellimagingofapoptosisonsetinSH-SY5Ycellstreatedfor72hwith
vehicle (A, a–d)o rb–hPrP90-231-FITC (100nM) (B, e–h). Apoptosis was assessed by annexin-V binding assay. Control cells (a–d) did not evidence red ﬂuorescence,
indicating the absence of annexin-V binding (a). Upon b–hPrP90-231-FITC treatment, red ﬂuorescent rings were detected, indicating apoptosis-induced PS exposure on the
externallayerofplasmamembranes(e,yellowarrows)thatwasparalleledbytheinternalizationoflargeamountsofﬂuorescentPrPfragmentinseveralcells(f,yellowarrows).
In cells in which only small quantities of b–hPrP90-231-FITC were detected (f, white arrows), we did not observe annexin b–hPrP90-231-FITC binding. Phase-contrast
pictures (g and h) evidences that the treatment with b–hPrP90-231-FITC caused cell body shrinkage. Images in panel H show that cell loading with high amounts of b–
hPrP90-231-FITCcorrelatewithannexin-Vstainingandcellbodyshrinkage(h,yellowarrows).(Scalebar¼10mm).Lowerpanels.Apoptosismeasurementbyﬂowcytometry
of annexin-V binding. SH-SY5Y cells were treated for 3 days with vehicle (A) and b–hPrP90-231-FITC (1mM) (B). Vehicle-treated cells showed a 3.97% of positivity to
annexin-V (A, R2); b–hPrP90-231-FITC treatment induced FITC staining in more than 87% of the cells (B, R5) and increased the percentage of annexin-V-positive/FITC
positive cells to 11.37 (B, R2) compared with untreated controls. Less than 1% of annexin-V-positive, FITC-negative (B, R2) cells were recorded
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Cell Death and DiseaseCells were lysed in non-denaturing conditions, insoluble
proteins collected by centrifugation, and the amount of
hPrP90-231 in soluble and insoluble fractions determined
by immunoblotting. PrP
C was recovered in the detergent-
soluble fraction at all the treatment times (Figure 4a),
whereas hPrP90-231 was detected only in the insoluble
fraction of cell lysate, in which it accumulates in a time-
dependent manner (Figure 4b).
Internalized hPrP90-231 displays partial resistance to
proteolysis. We measured PK sensitivity of internalized
hPrP90-231 to obtain an index of resistance to lysosomal
degradation. Cells treated with vehicle or hPrP90-231 were
lysed under non-denaturing conditions, in the absence of
protease inhibitors, and proteins incubated with increasing
amounts of PK (Figure 5a). In the absence of PK treatment,
endogenous PrP
C was detected without alterations induced
by hPrP90-231 treatment. Conversely, a large 3F4-
immunoreactive band was detectable in cell lysates after
treatment with hPrP90-231, showing an apparent molecular
weight matching with that of hPrP90-231 (16kDa). Although
PrP
C was completely degraded by PK (1mg), the complete
digestion of the bona ﬁde intracellular hPrP90-231 required a
10-fold higher PK concentration. The marked difference in
proteolysis resistance between PrP
C and internalized
hPrP90-231 was further demonstrated using the cell
blotting technique. Treated cells were ﬁrmly pressed on
lysis buffer-soaked nitrocellulose membrane to transfer their
protein content as a sort of ﬁngerprint; membranes were then
treated with PK before being probed with 3F4 and 8B4
antibodies (Figure 6). Immunoblots revealed that cells
exposed to hPrP90-231 retain a 3F4-immunoreactive
signal, resistant to PK digestion (up to 0.5mg/ml, upper
panel), whereas vehicle-treated cells showed an almost
complete loss of 3F4 signal. Using the 8B4 antibody (lower
panel), PK treatment markedly reduced the immunoreactive
signal in both vehicle and hPrP90-231-treated samples,
indicating a high PrP
C sensitivity to proteolysis that is not
modiﬁed by cell exposure to hPrP90-231.
hPrP90-231 is internalized into acidic organelles. SH-SY5Y
cells plated into glass-bottom Petri dishes were treated
with hPrP90-231-FITC, loaded with lysotracker red DND-99
that stains endosomal–lysosomal vesicles and analyzed by
confocal microscopy in live cell imaging. Intracellular hPrP90-
231-FITC was detected as ﬂuorescent clusters colocalized with
lysotracker (Figure 7a). Lysotracker-positive and hPrP90-231-
FITC-loaded vesicles showed larger size than those that do not
contain the peptide. To better analyze lysosomal involvement in
hPrP90-231 effects, we tested, by immunoblotting, the
expression of the active form of the lysosomal enzyme CD.
The amount of active CD was greatly increased after 2h,
peaked at 6h, and was still upregulated after 2 days of hPrP90-
231 treatment (Figure 7b), with a signiﬁcant temporal
relationship with intracellular accumulation of hPrP90-231
(Figure 4b). These data provide important evidence that cell
PrPC {
β–hPrP90-231
123 4 1234
12 3 4 2 3 4
Figure 3 Internalized b–hPrP90-231 forms SDS-stable aggregates. Cells were
treated with vehicle (lanes 2 a–d)o rb–hPrP90-231 (1mM) for 1 (lanes 3 a–d) and
4 days (lanes 4 a–d). Total cell lysates (100mg) were resolved by semi-denaturing
detergent-agarose gel electrophoresis (a and b) and SDS-PAGE (c and d). Blots
were probed with anti-PrP antibodies 3F4 (a and c) and 8B4 (b and d). Puriﬁed
b–hPrP90-231 (100ng, lanes 1 a–c) was subjected to both electrophoretic
conditions, to evidence its apparent molecular weight (c, lane 1), and native
aggregationstate(a,lane1).Nosignalisdetectedinlane1b,as8B4antibodydoes
notrecognizeb–hPrP90-231.Blota shows3F4-immunoreactiveaggregatesafter 1
and 4 days of treatment with hPrP90-231. Blot b shows that no signiﬁcant
8B4-reactive aggregates are induced by b–hPrP90-231 treatment. SDS-PAGE
shows that, although b–hPrP90-231 monomer is recovered within SH-SY5Y
cytoplasm after 1 and 4 days of treatment (blot c), the expression of endogenous
PrP
C is unmodiﬁed (blot d)
Soluble
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Figure 4 Internalized b–hPrP90-231 is insoluble in non-denaturing detergents.
Cells were treated with b–hPrP90-231 (1mM) for 1–48h. Cells were collected in
non-denaturing lysis buffer, cleared of debris, and centrifuged at 16000 g for
45min. Supernatants (a) and pellets (b) (50mg) were analyzed by western blot
using anti-PrP monoclonal antibody 3F4. Puriﬁed b–hPrP90-231 (100ng) (lane C)
was loaded to compare the electrophoretic run of PrP fragment before and after
intracellular uptake. b–hPrP90-231-treated cells evidence increased 3F4-immunor-
eative bands having an apparent molecular weight of 16KDa, corresponding to
b–hPrP90-231 (resolved in lane C). Intracellular b–hPrP90-231 is recovered in a
time-dependent manner in the pellets, indicating that internalized pepetide is
completely insoluble (b). Conversely, endogenous PrP
C is recovered almost
completely in the soluble fraction (a) and does not modify its expression upon cell
treatment with b–hPrP90-231
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Cell Death and Diseaseproteolytic machinery is activated in response to hPrP90-231
(i.e. accumulation within lysosomes and increase of CD activity),
but suggest that it is not sufﬁcient to remove hPrP90-231
from cells.
hPrP90-231 treatment induces loss of lysosomal
membrane impermeability. To test whether lysosome
overloading with protease-resistant hPrP90-231 aggregates
is responsible for SH-SY5Y apoptosis, we evaluated the
effects of PrP fragment internalization on lysosome
membrane impermeability. By confocal microscopy, we
monitored the intracellular distribution of the membrane-
impermeable liquid-phase dye LY. It is taken up by
endocytosis and accumulates within recycling endosomes,
late endosomes, and lysosomes.
19 In healthy cells,
lysosomes retain membrane impermeability that prevents
LY leakage in the cytosol, whereas lysosome-mediated
apoptosis is preceded by their membrane permeabilization
and release of LY and hydrolytic enzymes.
24 SH-SY5Y cells
were treated with vehicle or hPrP90-231 before being loaded
with LY and analyzed by confocal microscopy (Figure 7c). To
demonstrate LY loading in lysosomes, we also labeled
SH-SY5Y cells with lysotracker. Live cell analysis revealed
an almost complete ﬂuorescence overlapping between
lysotracker and LY in control cells, indicating that LY
efﬁciently loaded lysosomes, demonstrating their integrity.
Conversely, hPrP90-231-treated cells evidenced LY diffuse
staining within the cytoplasm, often losing the colocalization
with lysotracker (Figure 7c, lower panel). Thus, lysosomal
hydrolases, including CD that is activated after hPrP90-231
treatment (Figure 7b), may diffuse from lysosomes into the
cytosol to induce apoptosis. Hence, we investigated the
possibility that pharmacological blockade of CD could inhibit
the proapoptotic activity of hPrP90-231. For this purpose, we
pretreated SH-SY5Y cells with pepstatin A (Pep A), a speciﬁc
inhibitor of CD, before the incubation with hPrP90-231, and
measured cell viability and DNA cleavage by 3-(4,5-
dimethylthiazol-2-yl)2,5, diphenyl tetrazolium bromide
(MTT) reduction test and oligonucleosome ELISA,
respectively, (Table 2). Treatment with hPrP90-231
reduced cell viability and increased DNA cleavage as
compared with controls. Both the effects were signiﬁcant,
although not completely reduced by pre-treatment with Pep A
(10mM). Lower or higher concentrations of Pep A were either
ineffective or per se cytotoxic, respectively, (data not shown).
These data suggest that CD activation takes part in the
transduction of the proapoptotic activity of hPrP90-231,
although other CD-independent events could participate to
this process. More importantly, the demonstration of CD
involvementinhPrP90-231toxicityarguesinfavorofanactive
role of lysosomal permeabilization in the induction of
Ab:
3F4
Vehicle
a
b
β–hPrP90-231
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[PK] μg/ml
[PK] μg/ml
0 0.1 0.5
0.1 0.5
Ab:
8B4
β–hPrP990-231
0
Figure 6 Cell blotting analysis of internalized b–hPrP90-231 PK sensitivity.
Cells were plated on glass coverslips, treated with vehicle (PBS) or b–hPrP90-231
(1mM) for 24h, and processed for cell blotting (see Materials and methods). Blots
were treated with increasing concentrations of PK and probed with anti-PrP
antibodies3F4(a)and8B4(b).Vehicle-treatedcellsshowimmunoreactivityforboth
antibodies that is strongly reduced by PK treatment. b–hPrP90-231 treatment
induces a signiﬁcant PK resistance, evidenced only by 3F4 antibody
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Figure5 Internalizedb–hPrP90-231ispartlyPKresistant.(a)Cellstreatedwith
PBSorb–hPrP90-231(1mM)for24and48hwerecollectedinnon-denaturinglysis
buffer, without protease inhibitors.Proteinsfor each sample (100mg) were digested
with increasing concentrations of PK (1, 2, and 10mg/ml) at 371C for 30min. PrP
C
and b–hPrP90-231 digestion fragments were resolved by 15% SDS-PAGE using
the anti-PrP antibody 3F4. b–hPrP90-231 (100ng) was loaded to compare the
electrophoretic run of PrP fragment before and after intracellular uptake (lane
C). Control cells evidence a faint 3F4-immunoreactive signal between 35 and
45kDa, corresponding to PrP
C, that is almost fully digested by PK. Cell treatment
with b–hPrP90-231 for 24 and 48h induced the appearance of a 16kDa band
corresponding to internalized PrP fragment that showed a full digestion only at
10mg/ml PK, indicating that internalized b–hPrP90-231 is signiﬁcantly more
protease-resistant than PrP
C.( b) Densitometric analysis of 3F4 signal in untreated
(white columns) and PK-digested samples (light gray, gray, and black columns).
Time 0, in the absence of b–hPrP90-231, indicates PK effects on PrP
C (MW 35–
45kDa).Plotshowsthatintracellularb–hPrP90-231resistanceishigherthanthatof
PrP
c and increases with treatment time. Values (n¼3) represent OD intensity/mm
2
and expressed as percentage of respective PK-undigested samples. *Po0.05 and
**Po0.01 versus respective undigested controls;
OPo0.05,
OOPo0.01 versus
corresponding PK digestion of vehicle-treated cells
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Cell Death and Diseaseapoptosis, likely due to accumulation of aggregated,
protease-resistant PrP fragment.
Discussion
The relationship between PrP misfolding and neuronal death
is still debated.
25 In particular, the relevance of extracellular
deposition of PrP
Sc in disease progression is controversial,
being proposed to represent either a primary pathogenic
event, an epiphenomenon of neuronal death or a cell defense
reaction.
26 The endosomal–lysosomal system represents the
site of PrP
C–PrP
Sc interaction responsible for PrP
C misfolding
and PrP
Sc partial cleavage.
27 Vesicular trafﬁcking from
plasma membrane to lysosomes sustains intracellular accu-
mulationofPrP
Sc,
28leadstolysosomalimpairment,andmight
represent a mechanism of prion neurodegeneration.
15,16
Impairment of lysosomal activityalso contributes to Alzheimer
disease pathogenesis
29 with Ab peptides functioning as
seeds for amyloid formation in acidic vesicles.
22
In TSE, PrP
Sc uptake in neurons occurs in the early phases
of disease, allowing the formation of new PrP
Sc molecule and
their diffusion into surrounding neurons.
30,31 We character-
ized the events involved in PrP
Sc internalization as a cause of
neuronal death, using hPrP90-231 as an in vitro model of
prion neurotoxicity. This fragment encompasses the amino
acidsequenceofpeptidesderivedfromPrP
Scpartialdigestion
that occurs in prion-infected brains.
32 There are several
similarities between recombinant PrP fragments and PrP
Sc,
including structural ﬂexibility,
4 structure-dependent in vitro
cytotoxicity,
3,33 and, in particular experimental conditions,
infectivity,
5,6 supporting the hypothesis that in TSE patient
Vehicle
Lysotracker Lysotracker merge
Vehicle
CD
α-tubulin
30 KDa βhPrP90-231
48 24 6 2 0
Time (hrs.)
β-hPrP90-231-FITC
FITC
LY Lysotracker Merge
Figure 7 Intracellular b–hPrP90-231 activates endosomal–lysosomal system. (a) b–hPrP90-231-FITC accumulates into endosomal–lysosomal vesicles. Cells were
treated with vehicle and b–hPrP90-231FITC (1mM) for 24h and counterstained with lysotracker red DND-99, before being observed in live cell confocal microscopy. Cells
treated with b–hPrP90-231-FITC show ﬂuorescent round clusters that almost completely colocalize with lysotracker. Vehicle-treated cells were stained with lysotracker red to
provide images of lysosomes distribution and size in SH-SY5Y cells. (b) b–hPrP90-231 elicits the expression of active CD. Cells were treated for 2–48h with hPrP90-231
(1mM).TheamountofactiveCD(MW33kDa)wasdetectedbySDS-PAGE(10%),loading50mgofcellproteins/lane.Aseparatesetofsamples(10mg/lane)wasprobedwith
themonoclonalanti-a-tubulintonormalizeproteincontent.Theexpressionof33kDaCD,correspondingtothematureactiveform,issigniﬁcantlyincreasedafter2h,reachesa
sustained plateau after 6h, and lasts up to 48h of treatment. (c) b–hPrP90-231 treatment causes loss of lysosome membrane impermeability. Cells were treated for 3 days
with vehicle (PBS) or b–hPrP90-231 (1mM). In the last 15h of treatment, cells were loaded with 100mg/ml of LY. At 15min before confocal microscope analysis, cells were
loaded with lysotrackerred DND-99 (50nM). Control cells evidenceda vesiculardistributionof LY that almost completelyoverlaps with lysotracker ﬂuorescence, indicating an
efﬁcient loading of LY in endosomal–lysosomal vesicles (upper panels). b–hPrP90-231-treated cells exhibited a diffuse LY staining within the cytoplasm outside lysotracker-
positive vesicles (lower panel), indicating that LY has been redistributed in the cytosol following the loss of lysosomal membrane impermeability. (Scale bars¼10mm)
Table 2 Cathepsin D inhibition by pepstatin A inhibits SH-SY5Y cell death and
induction of apoptosis induced by b-hPrP90-231
Treatment
Cell viability
(% of control)
Apoptosis
(% of control)
Control 100 100
b-hPrP90-231 68±0.5* 297±0.12**
b-hPrP90-231+pepstatin A 80±0.7*
O 218±0.09**
OO
Pepstatin A 99±0.2 108±0.06
Cells were pretreated with pepstatin A (10mM) at 1h before b hPrP90-231
(1mM). Cell viability was measured by MTT reduction assay, and the extent of
apoptosis was detected using cytosolic oligonucleosome ELISA Data were
expressed as percentage of PBS-treated control cells and represents the
average of three independent experiments performed in quadruplicate
*Po0.05, **Po0.01 versus cont. values.
OPo0.05,
OOPo0.01 versus
hPrP90-231-treated values
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role in neuronal apoptosis.
We report that hPrP90-231 intracellular aggregates within
acidic vesicles are insoluble and partially resistant to
proteolysis. Using hPrP90-231-FITC, live cell imaging, and
confocal microscopy, we were able to discriminate between
the exogenous fragment and endogenous PrP
C, and avoid
possible artifacts caused by cell ﬁxation. We show that
hPrP90-231 binding to plasma membrane occurs within few
minutes and is followed by accumulation in intracellular
protein clusters that was dependent on the refolding of the
peptide in a b-sheet-rich conformer. We never observed
persistent membrane binding of hPrP90-231-FITC or sig-
niﬁcant accumulation of the protein across the plasma
membrane, the membrane-hPrP90-231 interaction being
mainly involved in the internalization of the PrP fragment. To
verifywhetherhPrP90-231aggregateresistancetolysosomal
proteolytic activity may be responsible for hPrP90-231
intracellular accumulation cytotoxicity, we analyzed three
biochemical parameters of the internalized peptide: aggrega-
tion state, insolubility, and PK sensitivity, all of them reliably
used to discriminate PrP
Sc from PrP
C.
1,34 The extent of
aggregation of internalized hPrP90-231, in semi-denaturing
detergent-agarose gel electrophoresis,was detected, as3F4-
immunoreactive signal smeared through all the lane, indicat-
ing the presence of aggregates composed by heterogeneous
number of molecules. 8B4 antibody, recognizing only
endogenous PrP
C, did not reveal aggregation, indicating that
most, if not all, 3F4 immunoreactivity detects hPrP90-231.
However, we cannot exclude the possibility that PrP
C may
function as a seed to allow or, at least, favor hPrP90-231
aggregation. The involvement of endogenous PrP
C in
hPrP90-231 aggregation is an intriguing issue deserving
further investigations.
Upon internalization, hPrP90-231-FITC is trapped into
phospholipid-surrounded vesicles having features of late
endosomes or lysosomes. Moreover, CD activation occurred
after cell exposure to hPrP90-231, strengthening the hypo-
thesis that SH-SY5Y cells actively uptake hPrP90-231 and
activate lysosome-mediated proteolysis, although hPrP90-
231 aggregates are not hampered by exposure to lysosomal
proteolytic activity. Using non-denaturing conditions to pre-
serve the aggregation state of internalized hPrP90-231, we
show that hPrP90-231 intracellular deposits are insoluble in
non-denaturing detergents and show a signiﬁcant higher PK
resistance than endogenous PrP
C. The ﬁnding that these
biochemicalfeaturesofhPrP90-231,previouslycharacterized
in cell-free models,
3,8 are enhanced after accumulation in
lyso-phagosomes, indicates that the proteolytic machinery of
SH-SY5Y cells is impaired by the progressive internalization
of high quantities of hPrP90-231 and this alteration could
represent a crucial event to trigger apoptosis. In particular,
hPrP90-231 partial resistance to PK likely reﬂects its ability to
withstand lysosomal degradation once endocyted. Lyso-
somes have been involved in TSE pathogenesis, as high
number of endosomal–lysosomal vesicles containing PrP
Sc
are detected in brains of scrapie-infected mice and CJD-
affected humans.
2,15,16
Lysosome-mediated apoptosis occurs when lysosome
membranes become permeable to proteolytic enzymes that,
once released, activate caspases or other proapoptotic
proteins.
35 Lysosomal membrane permeabilization occurs in
different neurotoxic conditions,
18 including Ab1–42 expo-
sure.
19 We report that intracellular hPrP90-231 accumulation
and the consequent lysosome damage correlates with the
onset of apoptosis. We calculated that at each time point
analyzed, about 10% of apoptotic cells were present in
hPrP90-231-treated cultures, although the required washing
steps may detach dying cells, underestimating the incidence
of apoptosis. We associated confocal microscopy observa-
tions to ﬂow cytometry results: FACS analysis revealed that
about 99% of total cells was stained with hPrP90-231-FITC,
but was unable to discriminate the majority of cells having
internalized, at a given time point, small amounts of hPrP90-
231 from those that have internalized massive amount of
hPrP90-231-FITC. By confocal living cell observation, we
revealed a threshold of hPrP90-231-FITC internalization
required to trigger the apoptotic cascade.
In search of a link between intralysosomal aggregation of
protease-insensitive hPrP90-231 and activation of lysosome-
dependent apoptosis, we measured lysosome ability to
segregate LY after exposure to hPrP90-231. We observed
that hPrP90-231 treatment affected vesicular distribution of
LY inducing its cytoplasmic diffusion. Whether LY diffusion
from lysosomes is a direct consequence of hPrP90-231
accumulationintheorganellesorresultsfromamorecomplex
toxic pathway triggered by PrP fragment, remains to be
established. However, we show that lysosomal enzymes, like
CD, are activated after hPrP90-231 treatment and, once
released into the cytosol, could start the apoptotic program.
Finally, a more direct relationship between lysosomal
dysfunction and hPrP90-231-induced cell death was demon-
strated by the reduction of SH-SY5 apoptosis in the presence
of the CD inhibitor Pep A, although, the effect being
incomplete, other intracellular effectors might have a role in
transducing cytotoxic signals of hPrP90-231. hPrP90-231
interaction with plasma membrane could also trigger apopto-
sis through the perturbation of ion homeostasis
36,37 or cell
responsiveness to neuroprotective factors.
10 We recently
demonstrated that hPrP90-231 leads to cell apoptosis
affecting the balance between MAP kinase activities, inhibit-
ing ERK1/2 and activating p38.
10 The molecular events that
precedes hPrP90-231 ERK1/2 inhibition are not identiﬁed,
and a link between lysosomal permeabilization and ERK1/2/
p38 imbalance has not been demonstrated.
Another important issue concerns the effect of hPrP90-231
aggregation state on the cells’ ability to internalize the
fragment. We demonstrated that large, but aggregated or
amyloid ﬁbrils of hPrP90-231 cannot be internalized and
cause cell death.
12 Thus, we propose that hPrP90-231
endocytosis is hampered by its extracellular aggregation,
although the threshold limit of this phenomenon is still
unknown. In this regard, the ﬁnding that intracellular
hPrP90-231 formed insoluble and PK-resistant aggregates
is particularly relevant, as it indicates that the aggregation
process of the protein has been allowed, if not favored, by the
intracellular milieu.
In conclusion, we propose a model in which neurotoxic PrP
is taken up by neurons in oligomeric soluble forms and
accumulate in acidic vesicles, in which aggregation takes
Lysosome destabilization by hPrP90-231
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dependent on the amount of internalized PrP molecules and
the capacity of these aggregates to cause lysosome-
dependent apoptosis.
Materials and Methods
Reagents and antibodies. FITC, lysotracker red DND-99, Annexin-V Alexa
Fluor 594 conjugate, DiI, LY CH, and Alexa Fluor-conjugated secondary antibodies
werefromMolecularProbes-Invitrogen (Milano,Italy);proteaseK andanti-a-tubulin
mouse monoclonal antibody were from Sigma-Aldrich (Milano, Italy); anti-PrP
mouse monoclonal antibody 3F4 was from Signet (London, UK), anti-PrP mouse
monoclonal antibody 8B4 and anti-CD rabbit polyclonal antibody were from Santa
Cruz, (Santa Cruz, CA, USA); horse peroxidase-linked anti-mouse and anti-rabbit
secondary antibodies were from GE Healthcare (Milano, Italy).
Recombinant hPrP90-231. The PrP fragment was obtained and puriﬁed as
previously described.
7 Before addition to cultures, hPrP90-231 was incubated at
531C for 1h
4 that causes its refolding in a b-sheet-rich conformer (native structure:
a-helix 42.4%, b-sheet 6.8%; after thermal denaturation: a-helix 8.6%, b-sheet
58.8%).
FluorescenthPrP90-231. FITCtagof hPrP90-231wasperformedby adding
1mg of FITC in 100ml DMSO to 5ml of hPrP90-231 solution (0.25mg/ml in PBS,
pH8.0).Incubationwascarriedfor30minunderdark-adaptedrotation.Thereaction
was stopped by adding glycine to reach a ﬁnal concentration of 10mM; ﬂuorescent
hPrP90-231(hPrP90-231-FITC)wasseparatedbyunboundFITCandconcentrated
by three centrifugation steps in Millipore (Cork, Ireland) centricon tubes (10ml,
10kDa mesh). hPrP90-231-FITC was used freshly or stored at  801C for not
longer than 15 days. Unless otherwise speciﬁed, hPrP90-231 was incubated for 1h
at 531C before FITC addition.
Cell cultures and treatments. SH-SY5Y human neuroblastoma cells were
cultured in Mem/F12 medium (Euroclone, Milano, Italy) supplemented with 15%
fetal bovine serum (FBS) (Gibco-Invitrogen, Milano, Italy), 2mM glutamine
(Euroclone), pen/strep 100mg/ml (Euroclone) and grown in 5% CO2 atmosphere
at 371C.
Treatments. At 24h after plating, unless otherwise stated, culture medium was
replaced with a fresh medium containing a reduced (2%) percentage of FBS to
induce growth arrest and minimize spontaneous apoptosis that serum withdrawal
causes in this cell model;
38 then, cells were treated by adding hPrP90-231 or
hPrP90-231-FITC directly to the medium.
Confocal analysis
Immunostaining. Cellswereplatedonglasscoverslips(Corning-Costar,Celbio,
Milano, Italy) and treated with hPrP90-231-FITC; to evidence cell shape, cells were
ﬁxed in cold methanol and immunostained with anti-a-tubulin antibody by following
standard procedures.
Live cell imaging. Cells were plated in glass-bottom Petri dishes (Iwaki, Bibby
Scientiﬁc, Milano, Italy) and loaded with 100ng/ml of DiI for 1h. Cells were then
rinsedinPBSandthentreatedwithhPrP90-231-FITCin2% FBS-containingculture
medium. At given time points, live cells were washed with serum-free medium and
observed using a inverted ﬂuorescent microscope (Nikon Eclipse TE300, Langen,
Germany) equipped with a laser scanning confocal system (Bio-Rad MRC1024 ES,
Bio-Rad Laboratories, Milano, Italy). When speciﬁed, lysotracker red DND-99
(50nM) was added to cell cultures 15min before the confocal observation.
MTT reduction assay. Mitochondrial function, as index of cell viability, was
evaluated by measuring MTT reduction into purple formazan crystals.
38 Cells were
incubated with 0.25mg/ml MTT in serum-free medium at 371C for 2h. Medium was
removedand formazanwas dissolved in DMSO;values of absorbance wereread in
a spectrophotometer at 570nm.
Apoptosis detection
Oligonucleosome release. The assay (cell death detection ELISA, Roche,
Monza, Italy) is based on a quantitative sandwich enzyme immunoassay principle
that determines the amount of mono-and oligonucleosomes, released in the
cytoplasm by apoptotic endonucleases.
3 Brieﬂy, after treatments, cytosolic fraction
of cell lysates were placed into streptavidin-coated microplate wells (Roche) and
incubated with a mixture of biotinylated anti-histone antibodies and peroxidase-
linked anti-DNA antibodies (Roche). Incubation and washing steps were performed
according to manufacturer’s instructions; peroxidase detection was determined
spectrophotometrically with ABTS as substrate.
Annexin-V binding test. This test evaluates apoptosis-induced exposure of
phosphatidylserine(PS)attheouterfaceofplasmamembranebystainingcellswith
the PS-binding protein annexin V.
39
Flow cytometry. We used Annexin V-APC Apoptosis Detection Kit I (BD
Biosciences, Oxford, UK) according to the manufacturer’s instructions. Brieﬂy,
control and hPrP90-231-FITC-treated cells were trypsinized, washed in PBS, and
resuspended in serum-free medium. Annexin V was added to the cell preparations
(10
5 cells) and incubated for 15min in the dark at room temperature (r.t.). Serum-
free medium was then added to each tube, and the samples were analyzed using
Cyan ADP cytoﬂuorimeter (Beckman-Coulter, Brea, CA, USA). For each sample,
20000 events were acquired. The data was analyzed using Summit 4.3.1 software
(Dakocytomation, Ely, Cambridgeshire, UK).
In situ studies. Cells were plated into glass-bottom Petri dishes (Iwaki) and
treatedwithhPrP90-231-FITC.Aftertreatments,cellswerewashedthreetimeswith
PBS and incubated with 1ml of annexin-V binding buffer (140mM NaCl, 10mM
HEPES, 2.5mM CaCl2, pH 7.4); subsequently, 50ml of annexin V Alexa Fluor
conjugate 594 antibody is addedfor 20min at r.t. After three washes with PBS, 1ml
of 2% FBS culture medium was added to allow observation of live cells under the
confocal ﬂuorescence microscopy. Although healthy cells evidence a scattered,
faint ﬂuorescent signal, apoptotic cells show a ﬂuorescent rim in correspondence
with the plasma membrane, indicating PS exposure.
Lysosome permeability assay. Cells were plated in glass-bottom Petri
dishes (Iwaki) and treated with hPrP90-231 (1mM). Then, cells were loaded
overnight with 100mg/ml of the cell impermeable liquid-phase tracer LY (Molecular
Probes)in2%FBSculturemedium.Afterthreewashingsteps,LYﬂuorescencewas
analyzed by confocal laser scanning. In healthy cells a vesicular distribution of LY is
observed, whereas lysosome membrane permeabilization results in a cytosolic
release of LY and a diffused cytoplasmic ﬂuorescence.
19
hPrP90-231 solubility assay. Cells were plated on 100mm Ø Petri dishes
and treated for 0, 1, 6, 24, and 48h with hPrP90-231 (1mM). After treatments, cells
werelysedin buffer(20mMTris-HCl,pH8, 130mMNaCl,2mMEDTA,0.5%Triton
X-100, 0.5% NP-40, 0.2% sodium deoxycholate, PMSF, protease inhibitor cocktail
(Roche)) and large debris were removed by centrifugation at 2000 g for 5min.
Supernatants were subjected to centrifugation at 16000 g for 45min. Protein
content was evaluated by Bradford assay. Samples from re-suspended pellets and
supernatants were boiled in the Laemmli buffer and resolved by SDS-PAGE. PrP
C
and hPrP90-231 content was determined by immunoblotting using the anti-PrP
mouse monoclonal antibody 3F4.
Intracellular hPrP90-231 PK resistance assay. Internalized hPrP90-
231 resistance to proteolysis was revealed by immunoblotting. Cells were plated on
100mmØPetridishes,treatedwithPBSorhPrP90-231(1mM)for24and48h,and
collected in lysis buffer without protease inhibitors. Total lysates were cleared of
nuclei/cell debris by brief centrifugation before protein content determination using
the Bradford assay (Bio-Rad). Digestion was performed treating 100mg of protein
for each sample with increasing concentrations of PK (ﬁnal concentration: 1, 2,
10mg/ml) for 30min at 371C. Digestion was stopped by boiling samples in Laemmli
buffer. Digestion proﬁle was detected by subjecting samples to 15% SDS-PAGE
followed by immunoblotting using the anti-PrP mouse monoclonal antibody 3F4.
Cell blotting. The intracellular presence of PK-resistant hPrP90-231 was
revealed through a modiﬁed version of cell blotting technique by Bosque et al.
40
Cells were plated on 15mm Ø glass coverslips at 70% conﬂuence and treated with
vehicle or hPrP90-231 (1mM) for 24h. After treatments, coverslips were gently
pressed for 2min, cells side-down on nitrocellulose soaked in lysis buffer without
protease inhibitors. Then membrane was air dried for 1h, washed in distilled water,
and incubated in lysis buffer containing PK (0.1 and 0.5mg/ml) for 1h at 371C with
constantshaking.Digestionwasstoppedbyincubatingtheblotfor20minwith5mM
phenylmethylsulfonyl ﬂuoride in dH2O at r.t. Blots were washed and blocked with
Tris-buffered saline, containing 5% non-fat dry milk, and incubated with mouse
monoclonal anti-PrP antibodies 8B4 and 3F4, following standard immunoblotting
procedures.
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buffer. Proteins were size fractionated by 10% or 15% SDS-PAGE and transferred
to a polyvinylidene diﬂuoride membrane (Bio-Rad Laboratories). Membranes were
blocked with 0.1% TBS-Tween containing 5% skim milk and then probed overnight
with the primary antibodies diluted in 0.1% TBS-Tween/5% skim milk. Secondary
antibodies were horseradish peroxidase-linked anti-mouse or anti-rabbit IgG
antiserum (GE Healthcare). Immunoreactivity was visualized by ECL (GE
Healthcare).
Semi-denaturing detergent-agarose gel electrophoresis. hPrP90-
231aggregation wasevaluatedasdescribed,
21with modiﬁcations.
20 After1–4days
of treatment, cells were lysed in 20mM Tris-HCl, pH 7.5, 130mM NaCl, 2mM
EDTA, 1% NP-40, 1mM PMSF, and protease inhibitor cocktail (Roche) and
centrifuged to remove nuclei and cell debris (1000r.p.m., 5min). Samples were
incubated for 10min at r.t. in loading buffer (60mM Tris-HCl, pH 7.5, 20% glycerol,
2% SDS, 0.05% bromophenol blue) and resolved on horizontal agarose gel (1.5%)
in TAE containing 0.1% SDS. After electrophoresis, proteins were transferred on a
nitrocellulose membrane (Hybond ECL, GE Healthcare) and probed with anti-PrP
mouse monoclonal antibodies 8B4 and 3F4. Immunoreactivity was detected with a
horseradish peroxidase-linked mouse antiserum followed by ECL.
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